BDNF and depressive symptom measurement: Thus, KREO prevents depression-like behavior by enhancing monoaminergic neurotransmission and attenuating hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, with these effects associated with activation of the BDNF signaling pathway.